| 纯度 | >= 80 % Purified via His tag |
| 种属 | Human |
| 靶点 | ACPP |
| Uniprot No | P15309 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 33 -386aa |
| 氨基酸序列 | KELKFVTLVF RHGDRSPIDT FPTDPIKESS WPQGFGQLTQ LGMEQHYELG EYIRKRYRKF LNESYKHEQV YIRSTDVDRT LMSAMTNLAA LFPPEGVSIW NPILLWQPIP VHTVPLSEDQ LLYLPFRNCP RFQELESETL KSEEFQKRLH PYKDFIATLG KLSGLHGQDL FGIWSKVYDP LYCESVHNFT LPSWATEDTM TKLRELSELS LLSLYGIHKQ KEKSRLQGGV LVNEILNHMK RATQIPSYKK LIMYSAHDTT VSGLQMALDV YNGLLPPYAS CHLTELYFEK GEYFVEMYYR NETQHEPYPL MLPGCSPSCP LERFAELVGP VIPQDWSTEC MTTNSHQGTE DSTDHHHHHH |
| 预测分子量 | 42 kDa |
| 蛋白标签 | His tag C-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ACPP(酸性磷酸酶，前列腺型)重组蛋白研究的示例文献摘要，供参考：
---
1. **文献名称**: *Targeted delivery of cytotoxic drugs using ACPP recombinant protein carriers*
**作者**: Smith J, et al.
**摘要**: 研究开发了一种基于ACPP重组蛋白的药物递送系统，利用其酸性微环境响应特性，将化疗药物靶向输送至肿瘤组织。体外实验表明，该系统显著增强药物在癌细胞中的积累，并减少对正常细胞的毒性。
2. **文献名称**: *Expression and functional analysis of ACPP recombinant protein in prostate cancer models*
**作者**: Lee H, et al.
**摘要**: 通过基因工程技术表达ACPP重组蛋白，并验证其在前列腺癌细胞中的生物学功能。研究发现，ACPP重组蛋白可通过调控PI3K/AKT信号通路抑制肿瘤细胞增殖并诱导凋亡。
3. **文献名称**: *ACPP recombinant protein as a potential biomarker for metastatic cancer diagnosis*
**作者**: Johnson R, et al.
**摘要**: 探讨ACPP重组蛋白在血清中的表达水平与癌症转移的相关性。临床样本分析显示，高浓度ACPP与乳腺癌和前列腺癌的骨转移显著相关，提示其作为诊断标志物的潜力。
4. **文献名称**: *Structural optimization of ACPP recombinant protein for enhanced stability and activity*
**作者**: Zhang Y, et al.
**摘要**: 通过定点突变和分子动力学模拟优化ACPP重组蛋白的结构，提高其在体内的稳定性和酶活性。改造后的蛋白在动物模型中表现出更强的抗肿瘤效果和更长的半衰期。
---
注：以上文献信息为示例，实际引用需以真实发表的论文为准。建议通过PubMed、Google Scholar等平台检索关键词“ACPP recombinant protein”或“prostatic acid phosphatase recombinant”获取具体文献。
ACPP (Acid Phosphatase, Prostate), also known as prostate acid phosphatase (PAP), is a glycoprotein enzyme primarily expressed in prostate epithelial cells. Historically recognized as a biomarker for prostate cancer, ACPP catalyzes the hydrolysis of phosphate esters in an acidic environment. Its elevated levels in serum were once a key diagnostic indicator for metastatic prostate cancer before the widespread adoption of prostate-specific antigen (PSA) testing.
In the 2000s, research revealed that ACPP plays roles beyond its enzymatic activity, including immune modulation and bone metabolism. This expanded understanding spurred interest in recombinant ACPP production for biomedical applications. Recombinant ACPP proteins are typically generated using expression systems like Escherichia coli or mammalian cell cultures, enabling precise control over post-translational modifications critical for functional studies.
A breakthrough emerged with the development of ACPP-based fusion proteins for targeted drug delivery. Scientists engineered ACPP to include cell-penetrating peptides (CPPs) that selectively localize to acidic tumor microenvironments or bone resorption areas. These smart biologics demonstrate potential in delivering chemotherapeutic agents or imaging probes to specific tissues while minimizing systemic toxicity.
Current research focuses on optimizing ACPP's structure-function relationships through protein engineering, particularly its pH-sensitive conformational changes and substrate-binding domains. Challenges remain in enhancing tissue specificity and stability, with ongoing clinical trials evaluating ACPP-linked therapies for prostate cancer and osteoporosis. The protein's dual role as a biological tool and therapeutic candidate continues to drive innovation in precision medicine and diagnostic technologies.
×
